Several members of the Alliance wrote to Senate Finance Committee Chairman Grassley (R-IA) and Ranking Member Wyden (D-OR), expressing concern about a reimbursement cap on the Average Sales Price (ASP) add-on proposed in the Prescription Drug Pricing Reduction Act (S.2543). The letter points out that reducing physician reimbursement for acquiring, storing, handling, and administering Part B drugs will do nothing to reduce the prices of the underlying products. Additionally, reductions in the ASP add-on disproportionately harm small and rural practices, who already experience difficulty acquiring medicines at ASP.
